James A Gallagher Selected Research

nitisinone (Orfadin)

5/2022	Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.
1/2022	Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
1/2021	Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.
1/2021	Characterising the arthroplasty in spondyloarthropathy in a large cohort of eighty-seven patients with alkaptonuria.
9/2020	Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.
1/2020	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
1/2020	Nitisinone causes acquired tyrosinosis in alkaptonuria.
1/2020	Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
7/2019	Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.
1/2019	A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James A Gallagher Research Topics

Disease

30	Alkaptonuria 07/2022 - 10/2010
13	Ochronosis 01/2021 - 11/2010
3	Osteoarthritis 01/2020 - 06/2015
3	Inborn Genetic Diseases (Disease, Hereditary) 12/2019 - 11/2010
2	Disease Progression 01/2022 - 01/2020
2	Spondylarthropathies 01/2021 - 01/2021
2	Tyrosinemias (Tyrosinemia) 01/2020 - 01/2019
2	Joint Diseases (Joint Disease) 01/2014 - 02/2011
2	Inflammation (Inflammations) 05/2008 - 01/2003
1	Rare Diseases (Rare Disease) 01/2020
1	Tyrosinosis 01/2020
1	Bone Fractures (Bone Fracture) 01/2017
1	Stress Fractures (Stress Fracture) 03/2016
1	Bone Resorption 06/2015
1	Bone Diseases (Bone Disease) 06/2015
1	Cartilage Diseases (Cartilage Disease) 06/2015
1	Osteosarcoma (Osteogenic Sarcoma) 10/2014
1	Metabolic Diseases (Metabolic Disease) 01/2014
1	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2008
1	Necrosis 09/2005

Drug/Important Bio-Agent (IBA)

19	Homogentisic AcidIBA 01/2021 - 11/2010
16	nitisinone (Orfadin)FDA Link 05/2022 - 01/2014
10	Tyrosine (L-Tyrosine)FDA Link 07/2022 - 02/2011
9	Homogentisate 1,2-Dioxygenase (Homogentisate 1,2 Dioxygenase)IBA 07/2022 - 10/2010
7	EnzymesIBA 07/2022 - 02/2011
3	CollagenIBA 01/2021 - 12/2011
2	Phenylalanine (L-Phenylalanine)FDA Link 01/2020 - 01/2015
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 09/2015
2	PolymersIBA 01/2014 - 05/2013
2	Melanins (Melanin)IBA 05/2013 - 11/2010
2	Adenosine Triphosphate (ATP)IBA 05/2008 - 01/2003
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Amino Acids FDA Link 01/2020
1	Dietary ProteinsIBA 01/2020
1	4-hydroxyphenylpyruvic acidIBA 01/2019
1	DioxygenasesIBA 01/2019
1	Purinergic P2X7 ReceptorsIBA 03/2016
1	Diphosphonates (Bisphosphonates)IBA 06/2015
1	Cathepsin KIBA 06/2015
1	Adiponectin ReceptorsIBA 10/2014
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 02/2011
1	AntioxidantsIBA 10/2010
1	CalciumIBA 05/2008
1	BradykininIBA 05/2008
1	Parathyroid Hormone-Related ProteinIBA 05/2008
1	Interleukin-1beta (Interleukin 1 beta)IBA 09/2005
1	Dinoprostone (PGE2)FDA Link 09/2005
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 09/2005
1	CytokinesIBA 09/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2005
1	Purinergic Receptors (Receptors, Purine)IBA 01/2003

Therapy/Procedure

8	Therapeutics 01/2021 - 06/2015
1	Arthroplasty 01/2021
1	Diet Therapy (Therapy, Diet) 01/2020
1	Replacement Arthroplasty 01/2017